Thomas Adam Abrams
Dana-Farber Cancer Institute · 245 works · 8,671 citations · h-index 39
Top works
- Hepatobiliary Cancers
- Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
- Futibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma
- NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017
- Identification of Potentially Avoidable Hospitalizations in Patients With GI Cancer
- Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study
- Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
- Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer
- Guidelines Insights: Hepatobiliary Cancers, Version 2.2019
- Phase 1/2 study of everolimus in advanced hepatocellular carcinoma
- NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023
- Feasibility of Computer-Based Self-Administered Cancer-Specific Geriatric Assessment in Older Patients With Gastrointestinal Malignancy
- Hepatobiliary Cancers, Version 2.2014
- First-in-Man Phase I Study of GC33, a Novel Recombinant Humanized Antibody Against Glypican-3, in Patients with Advanced Hepatocellular Carcinoma
- Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer
- Chemotherapy Usage Patterns in a US-Wide Cohort of Patients With Metastatic Colorectal Cancer
- A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma
- Patterns of Adjuvant Chemotherapy Use in a Population-Based Cohort of Patients With Resected Stage II or III Colon Cancer
- Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial
- A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma